DNPH1i (N6-benzyladenosine,BAPR) is a competitive inhibitor of adenosine deaminase(ADA) from L-1210 cells in axenic culture as well as a potent antiproliferative agent in vitro and in vivo.
DNPH1i is the DNPH1 competitive inhibitor, that co-treatmented with hmdU selectively kills the HR-deficient cells, BRCA1-defective cells and PARPi-resistant BRCA1-mutant cell lines depleted of PARP1, sensitizing BRCA-deficient cells to PARPi or hmdU treatment.[2]
[1] Tritsch GL, et al. Cancer Biochem Biophys. 1977;2(2):87-90. [2] Fugger K, et al. Science. 2021 Apr 9;372(6538):156-165.